ADHD Therapeutics Market to 2018 – New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 ADHD Therapeutics Market to 2018 – Introduction 8
2.1 Etiology and Pathophysiology 8
2.1.1 Genetic Influences 8
2.1.2 Environmental Influences 8
2.1.3 Pathophysiology 8
2.2 Epidemiology 9
2.2.1 Child/Adult Subpopulations 9
2.2.2 Male/Female 9
2.3 Diagnosis 9
2.3.1 DSM-IV Criteria for ADHD 9
2.3.2 ICD-10 Criteria for Hyperkinetic Disorder 12
2.3.3 Diagnostic Rating Scales 13
2.3.4 Issues with Diagnosis 13
2.3.5 Co-Morbid Disorders 14
2.4 Treatment and Management Options 15
2.4.1 Pharmacologic Treatment 15
2.5 Drivers and Barriers for ADHD Therapeutics Market 15
2.5.1 Drivers 15
2.5.2 Barriers 16
3 ADHD Therapeutics: Market Characterization by Geography 17
3.1 All Major Markets 17
3.1.1 Market Size – All Major Markets 17
3.1.2 Market Forecast – All Major Markets 18
3.1.3 Annual Cost of Therapy – Average of All Major Markets 19
3.2 The US 20
3.2.1 Market Size – The US 20
3.2.2 Market Forecast – The US 21
3.2.3 Annual Cost of Therapy – The US 21
3.3 Top 5 Countries of Europe 22
3.3.1 Market Size – France 22
3.3.2 Market Forecast – France 22
3.3.3 Annual Cost of Therapy – France 23
3.3.4 Market Size – Germany 24
3.3.5 Market Forecast – Germany 24
3.3.6 Annual Cost of Therapy – Germany 25
3.3.7 Market Size – Italy 26
3.3.8 Market Forecast – Italy 26
3.3.9 Annual Cost of Therapy – Italy 27
3.3.10 Market Size – Spain 28
3.3.11 Market Forecast – Spain 28
3.3.12 Annual Cost of Therapy – Spain 29
3.3.13 Market Size – The UK 30
3.3.14 Market Forecast – The UK 30
3.3.15 Average Annual Cost of Therapy – The UK 31
3.4 Japan 32
3.4.1 Market Size – Japan 32
3.4.2 Market Forecast – Japan 33
3.4.3 Annual Cost of Therapy – Japan 33
4 ADHD Therapeutics Market to 2018 – Competitive Landscape 34
4.1 Overview of Major Marketed Products in the ADHD market 34
4.1.1 Adderall XR (mixed amphetamine salt) 34
4.1.2 Daytrana (methylphenidate transdermal patch) 35
4.1.3 Concerta (methylphenidate hydrochloride) 36
4.1.4 Intuniv (guanfacine) 36
4.1.5 Strattera (atomoxetine hydrochloride) 37
4.1.6 Vyvanse (lisdexamfetamine dimesylate) 38
4.1.7 Kapvay (clonidine hydrochloride) 39
4.1.8 Focalin XR (dexmethylphenidate hydrochloride) 40
4.1.9 Generic products 40
5 ADHD Therapeutics Market to 2018 – Product Pipeline Analysis 41
5.1 Introduction 41
5.2 ADHD Therapeutics Pipeline – Pipeline by Phases of Development 41
5.3 Trends in the ADHD Therapeutic Pipeline 44
6 ADHD Therapeutics Market to 2018 – Strategic Consolidations 48
6.1 Overview 48
6.1.1 Deals by Deal Type 48
6.1.2 Deals by Year 49
6.1.3 Deals by Geography 49
6.1.4 Deals by Value 50
6.2 M&A Landscape 51
6.2.1 M&A Deals by Deal Type 51
6.2.2 M&A Deals by Year 52
6.2.3 M&A Deals by Geography 53
6.2.4 M&A Deals by Deal Value 54
6.2.5 Sanofi-Aventis Merger, 2004 54
6.3 R&D Licensing Agreements 55
6.3.1 Deals by Year 55
6.3.2 Deals by Geography 56
6.3.3 Deals by Deals Value 57
6.3.4 Targacept and AstraZeneca Agreement, 2009 57
6.4 Co-Development Agreements 58
6.4.1 Deals by Year 58
6.4.2 Deals by Geography 59
6.4.3 Deals by Deal Value 60
6.4.4 Shire and New River Co-Development Deal, 2005 60
7 Appendix 61
7.1 Abbreviations 61
7.2 Sources 61
7.3 Research Methodology 62
7.3.1 Coverage 62
7.3.2 Secondary Research 62
7.3.3 Primary Research 62
7.3.4 Market Size by Geography 65
7.4 Geographical Landscape 66
7.5 Pipeline Analysis 66
7.6 Competitive Landscape 66
7.6.1 Expert Panel Validation 66
7.7 Contact Us 66
7.8 Disclaimer 66